Status:
COMPLETED
GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Type2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.
Detailed Description
A randomized, placebo controlled study. Using a GIP receptor antagonist, we will investigate the glucose lowering effect of GIP during treatment with DPP-4 inhibitors.
Eligibility Criteria
Inclusion
- type 2 diabetes, treatment: lifestyle changes or metformin
- HbA1c \< 75 mmol/mol
Exclusion
- diagnosed liver disease
- eGFR \< 60 ml/min/1,73m2
- NYHA III or IV
- anemia.
Key Trial Info
Start Date :
May 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03845179
Start Date
May 29 2019
End Date
February 28 2020
Last Update
March 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark, 2900